DNA X, Inc.

For the period ended Mar 31, 2026. Filed May 20, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 20, 2026

SONM$2.22+4.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)

	Three Months Ended March 31,
	2026	2025
Continuing operations:
Net revenues	$—	$—
Operating expenses
General and administrative	3,618	870
Total operating expenses	3,618	870
Net loss from operations	(3,618)	(870)
Interest expense, net	(131)	(91)
Loss on remeasurement of derivative liability	(227)	—
Equity income from DNA X LLC	48	—
Net loss from continuing operations before income taxes	(3,928)	(961)
Income tax expense from continuing operations	—	—
Net loss from continuing operations	(3,928)	(961)
Discontinued Operations:
Income from discontinued operations, net of tax	10,268	1,419
Net income	$6,340	$458
Net earnings (loss) per share basic and diluted:
Continuing operations*	(3.11)	(2.96)
Discontinued operations*	8.12	4.37
Net income*	$5.01	$1.41
Weighted-average shares used in computing net loss per share:
Basic and diluted*	1,265,067	324,431

*	Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements*.*

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.